Mechanistic insights into the aggregation pathway of the patient-derived immunoglobulin light chain variable domain protein FOR005

被引:0
作者
Tejaswini Pradhan
Riddhiman Sarkar
Kevin M. Meighen-Berger
Matthias J. Feige
Martin Zacharias
Bernd Reif
机构
[1] Technical University Munich,Bavarian NMR Center (BNMRZ), Department of Bioscience, TUM School of Natural Sciences
[2] Helmholtz-Zentrum München (HMGU),Institute of Structural Biology (STB)
[3] Technical University Munich,Center for Functional Protein Assemblies (CPA), Department of Bioscience, TUM School of Natural Sciences
来源
Nature Communications | / 14卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Systemic antibody light chain (AL) amyloidosis is characterized by deposition of amyloid fibrils. Prior to fibril formation, soluble oligomeric AL protein has a direct cytotoxic effect on cardiomyocytes. We focus on the patient derived λ-III AL variable domain FOR005 which is mutated at five positions with respect to the closest germline protein. Using solution-state NMR spectroscopy, we follow the individual steps involved in protein misfolding from the native to the amyloid fibril state. Unfavorable mutations in the complementary determining regions introduce a strain in the native protein structure which yields partial unfolding. Driven by electrostatic interactions, the protein converts into a high molecular weight, oligomeric, molten globule. The high local concentration of aggregation prone regions in the oligomer finally catalyzes the conversion into fibrils. The topology is determined by balanced electrostatic interactions in the fibril core implying a 180° rotational switch of the beta-sheets around the conserved disulfide bond.
引用
收藏
相关论文
共 108 条
[1]  
Blancas-Mejia LM(2013)Systemic amyloidoses Ann. Rev. Biochem. 82 745-774
[2]  
Ramirez-Alvarado M(2005)Clinical aspects of systemic amyloid diseases Biochim. Biophys. Acta 1753 11-22
[3]  
Obici L(2008)Amyloidosis: is a cure possible? Ann. Oncol. 19 63-66
[4]  
Perfetti V(2013)A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis Blood 121 3420-3427
[5]  
Palladini G(2001)Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts Circulation 104 1594-1597
[6]  
Moratti R(2006)Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL Blood 107 3854-3858
[7]  
Merlini G(2010)Cytotoxicity of amyloidogenic immunoglobulin light chains in cell culture Cell Death Dis. 1 e98-3531
[8]  
Merlini G(2007)Structural characterization of the partially folded intermediates of an immunoglobulin light chain leading to amyloid fibrillation and amorphous aggregation Biochemistry 46 3521-8104
[9]  
Palladini G(2003)Structural transformations of oligomeric intermediates in the fibrillation of the immunoglobulin light chain LEN Biochemistry 42 8094-3168
[10]  
Wechalekar AD(2019)Mechanistic insights into the early events in the aggregation of immunoglobulin light chains Biochem 58 3155-124